Extended Data Fig. 8: Diminished basal ECAR in KRAS-mutant tumour cells in which KRAS exon 4A is disrupted.

a, b, ECAR measured by Seahorse XFe96 of A549 (a) and SUIT2 (b) cells with or without disruption of KRAS exon 4A by CRISPR–Cas9. Oligomycin inhibits oxidative phosphorylation and allows the glycolytic reserve to be measured. 2-DG inhibits glycolysis. Data are mean ± s.e.m. (n = 10 technical replicates).